More recently, studies have suggested that RT-PCR for BCR::ABL1 may not be the best measure of MRD in several cases of Ph+ ALL and that a high sensitivity next-generation sequencing (NGS)-based immunosequencing assay (clonoSEQ) could potentially offer a more accurate assessment of prognosis [36,37]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.